Rituximab in cryoglobulinemic peripheral neuropathy
- 239 Downloads
Type II mixed cryoglobulinemia is sustained by an oligoclonal production of IgM sharing rheumatoid activity and can be associated with renal, cutaneous, rheumatologic or neurological manifestations. Peripheral neuropathy is a major cause of morbidity in hepatitis C virus-associated mixed cryoglobulinemia and is often refractory to any treatment. Rituximab induces a selective depletion of IgM-producing B cells, and both case reports on monoclonal IgM-related polyneuropathy as well as studies on small series of patients with interferon α-resistant mixed cryoglobulinemia have suggested that it may be beneficial. Thirteen patients affected by type II mixed cryoglobulinemia with polyneuropathy were treated. Rituximab was administered intravenously at a dose of 375 mg/m2 on days 1, 8, 15 and 22. Two more doses were given 1 and 2 months later. No other immunosuppressive drugs were added. Response was evaluated by assessing the changes in the clinical neurological condition, in electromyographic indices and in laboratory parameters (including cryocrit, viral load, complement levels and rheumatoid factor) over at least 12 months. Sensory symptoms disappeared or improved following treatment. A significant improvement in the clinical neuropathy disability score was observed. Electromyography examination revealed that the amplitude of compound motor action potential had increased. Viral load did not significantly change. Side effects were negligible. In this open prospective study, rituximab appeared to be effective and safe in the treatment of patients with type II cryoglobulinemia-associated neuropathy.
KeywordsHCV-related mixed cryoglobulinemia Cryoglobulinemic peripheral neuropathy Rituximab
We would like to thank Sara Bonello, Roberto Del Mastro and Guido Lombardi for their assistance in performing electrophysiologic studies.
Conflict of interest statement
- 1.Alpa M, Ferrero B, Cavallo R, Perna A, Naretto C, Gennaro M, Di Simone D, Bellizia L, Mansouri M, Rossi D, Modena V, Giachino O, Sena LM, Roccatello D (2007) Anti-GM1 and anti-sulfatide antibodies in patients with systemic lupus erythematosus, Sjögren’s syndrome, mixed cryoglobulinemia and idiopathic systemic vasculitis. Clin Exp Rheumatol 25(4):556–562PubMedGoogle Scholar
- 4.Benedetti L, Briani C, Grandis M, Vigo T, Gobbi M, Ghiglione E, Carpo M, Cocito D, Caporale CM, Sormani MP, Mancardi GL, Nobile-Orazio E, Schenone A (2007) Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 12:102–107PubMedCrossRefGoogle Scholar
- 12.Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84(10):3336–3343PubMedGoogle Scholar
- 17.Koskinas J, Kilidireas C, Karandreas N, Kountouras D, Savvas S, Hadziyannis E, Archimandritis AJ (2007) Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study. Liver Int 27(3):414–420PubMedCrossRefGoogle Scholar
- 23.Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC (1997) A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 63(1):28–34PubMedCrossRefGoogle Scholar
- 27.Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ (2004) Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 99(7):1298–1305PubMedCrossRefGoogle Scholar
- 31.Roccatello D, Morsica G, Picciotto G, Cesano G, Ropolo R, Bernardi MT, Cacace G, Cavalli G, Sena LM, Lazzarin A, Piccoli G, Rifai A (1997) Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection. Clin Exp Immunol 110(1):9–14PubMedCrossRefGoogle Scholar
- 32.Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco G, Sena LM (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19(12):3054–3061PubMedCrossRefGoogle Scholar
- 33.Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, Ponzetto A, Moriconi L, Pani A, Rustichelli R, Di Belgiojoso GB, Comotti C, Quarenghi MI (2007) Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49(1):69–82PubMedCrossRefGoogle Scholar
- 38.Zaltron S, Puoti M, Liberini P, Antonini L, Quinzanini M, Manni M, Forleo MA, Rossi S, Spinetti A, Zanini B, Carosi G (1998) High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. Ital J Gastroenterol Hepatol 30(4):391–395PubMedGoogle Scholar